Pulmatrix, Inc. (PULM)
Market Cap | 7.38M |
Revenue (ttm) | 7.30M |
Net Income (ttm) | -14.12M |
Shares Out | 3.65M |
EPS (ttm) | -3.87 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,089 |
Open | 2.030 |
Previous Close | 2.090 |
Day's Range | 2.020 - 2.052 |
52-Week Range | 1.550 - 3.140 |
Beta | 0.95 |
Analysts | Strong Buy |
Price Target | 10.00 (+395.05%) |
Earnings Date | May 10, 2024 |
About PULM
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trial... [Read more]
Financial Performance
In 2023, Pulmatrix's revenue was $7.30 million, an increase of 20.21% compared to the previous year's $6.07 million. Losses were -$14.12 million, -25.03% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PULM stock is "Strong Buy" and the 12-month stock price forecast is $10.0.
News
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a signif...
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix P...
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in H2 20...
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine BEDFORD,...
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazole Pulmatrix is currently enrolli...
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Subject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active sites to date in four countries, and topline data anticipated in Q3...
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
LEXINGTON, Mass. , July 11, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to ad...
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society
LEXINGTON, Mass. , June 15, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and cen...
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine LEXINGTON, Mass. , May 24, 2023 /PRNewswire/ -- Pulmatri...
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in cash and cash equivalents at the end of Q1 2023...
Pulmatrix Supports World Asthma Day 2023
LEXINGTON, Mass. , May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and cent...
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 pro...
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
LEXINGTON, Mass. , Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
LEXINGTON, Mass. , Jan. 25, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE PUR3100 demonstrated a five-minute Tmax and Cmax within the targeted therapeutic range for all three doses tested LEXINGTON,...
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash and cash equivalents at end of Q3 2022 LEXINGTON,...
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
Company is evaluating its iSPERSE™ orally inhaled dry powder formulation of dihydroergotamine (DHE) for treatment of acute migraine and expects pharmacokinetic data from the Phase 1 study in Q4 2022 L...
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Pulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2 with $42.9 million in cash and cash equivalents LEXINGTON, Mass. , ...
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
LEXINGTON, Mass. , July 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass. , May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceut...
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
LEXINGTON, Mass. , March 29, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and n...
Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results
Pulmatrix Inc (NASDAQ: PULM) announced topline results of its recently completed Phase 1b clinical study of PUR1800 in patients with stable Chronic Obstructive Pulmonary Disease (COPD). PUR1800 is a n...
Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD
LEXINGTON, Mass. , March 21, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and no...
Pulmatrix Regains Compliance With Nasdaq Listing Requirements
LEXINGTON, Mass., March 17, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non...